Condition
Relapsed Pediatric AML
Total Trials
6
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (2)
P 2 (2)
Trial Status
Unknown3
Completed1
Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07156435Phase 1RecruitingPrimary
Vyxeos® With Clofarabine for Pediatric AML
NCT05622591Phase 1Withdrawn
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
NCT04562792Phase 2Completed
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
NCT04033627Not ApplicableUnknown
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
NCT02638428Phase 2Unknown
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
NCT03245424Unknown
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
Showing all 6 trials